Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy

Open access
Lee, Jin-Ku, Liu, Zhaoqi, Sa, Jason K., Shin, Sang, Wang, Jiguang, Bordyuh, Mykola, Cho, Hee Jin, Elliott, Oliver, Chu, Timothy, Choi, Seung Won, Rosenbloom, Daniel I. S., Lee, In-Hee, Shin, Yong Jae, Kang, Hyun Ju, Kim, Donggeon, Kim, Sun Young, Sim, Moon-Hee, Kim, Jusun, Lee, Taehyang, Seo, Yun Jee, Shin, Hyemi, Lee, Mijeong, Kim, Sung Heon, Kwon, Yong-Jun, Oh, Jeong-Woo, Song, Minsuk, Kim, Misuk, Kong, Doo-Sik, Choi, Jung Won, Seol, Ho Jun, Lee, Jung-Il, Kim, Seung Tae, Park, Joon Oh, Kim, Kyoung-Mee, Song, Sang-Yong, Lee, Jeong-Won, Kim, Hee-Cheol, Lee, Jeong Eon, Choi, Min Gew, Seo, Sung Wook, Shim, Young Mog, Zo, Jae Ill, Jeong, Byong Chang, Yoon, Yeup, Ryu, Gyu Ha, Kim, Nayoung K. D., Bae, Joon Seol, Park, Woong-Yang, Lee, Jeongwu, Verhaak, Roel G. W., Iavarone, Antonio, Lee, Jeeyun, Rabadan, Raul, Nam, Do-Hyun · 2018 · Nature Genetics

Abstract

Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors to guide optimal patient-tailored therapy. Towards this goal, we have established a compilation of pharmacological landscapes of 462 patient-derived tumor cells (PDCs) across 14 cancer types, together with genomic and transcriptomic profiling in 385 of these tumors. Compared with the traditional long-term cultured cancer cell line models, PDCs recapitulate the molecular properties and biology of the diseases more precisely. Here, we provide insights into dynamic pharmacogenomic associations, including molecular determinants that elicit therapeutic resistance to EGFR inhibitors, and the potential repurposing of ibrutinib (currently used in hematological malignancies) for EGFR-specific therapy in gliomas. Lastly, we present a potential implementation of PDC-derived drug sensitivities for the prediction of clinical response to targeted therapeutics using retrospective clinical studies. Analysis of genomic and transcriptomic data from 462 patient-derived tumor cell (PDC) samples across 14 cancer types, along with pharmacological responses to 60 agents, indicates that PDC-derived drug sensitivities might be predictive of clinical response to targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-018-0209-6

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 203

Metadata

Authors
Lee, J.-K., Liu, Z., Sa, J. K., Shin, S., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., Rosenbloom, D. I. S., Lee, I.-H., Shin, Y. J., Kang, H. J., Kim, D., Kim, S. Y., Sim, M.-H., Kim, J., Lee, T., Seo, Y. J., Shin, H., Lee, M., Kim, S. H., Kwon, Y.-J., Oh, J.-W., Song, M., Kim, M., Kong, D.-S., Choi, J. W., Seol, H. J., Lee, J.-I., Kim, S. T., Park, J. O., Kim, K.-M., Song, S.-Y., Lee, J.-W., Kim, H.-C., Lee, J. E., Choi, M. G., Seo, S. W., Shim, Y. M., Zo, J. I., Jeong, B. C., Yoon, Y., Ryu, G. H., Kim, N. K. D., Bae, J. S., Park, W.-Y., Lee, J., Verhaak, R. G. W., Iavarone, A., Lee, J., Rabadan, R., & Nam, D.-H.
Venue
Nature Genetics
Published
2018-09-27
Volume
50
Issue
10
Pages
1399-1411
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2893221764
Cited by
203
References
31
FWCI
6.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. https://app.cochat.ai/papers/10.1038/s41588-018-0209-6
The paper
Lee, J.-K., Liu, Z., Sa, J. K., Shin, S., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., Rosenbloom, D. I. S., Lee, I.-H., Shin, Y. J., Kang, H. J., Kim, D., Kim, S. Y., Sim, M.-H., Kim, J., Lee, T., . . . Nam, D.-H. (2018). Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics. https://doi.org/10.1038/s41588-018-0209-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.